

5-24-05

1632  
170/150

JENKINS  
WILSON  
& TAYLOR

patent attorneys

May 23, 2005



"Express Mail" mailing number: EV 412 493 025 US

Date of Deposit: May 23, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Christi A. Butner*  
Christi A. Butner

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 08/999,690 for  
VECTORS CARRYING THERAPEUTIC GENES ENCODING  
ANTIMICROBIAL PEPTIDES FOR GENES THERAPY  
Our Ref. No. 1406/205

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (7 pages) in duplicate;
3. Cited references (83 references) in computer readable form (in duplicate);
4. Statement That Computer Readable Copies are the Same (1 page); and
5. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

*Arles A. Taylor, Jr.*


Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/JD/cab  
Enclosures  
Customer No: 25297


tel 919.493.8000  
fax 919.419.0383

Jenkins, Wilson & Taylor, P.A.  
JenkinsWilsonTaylor.com

University Tower, Suite 1400 | 3100 Tower Boulevard | Durham, North Carolina 27707



"Express Mail" mailing number.: EV 412 493 025 US  
Date of Deposit: May 23, 2005  
I hereby certify that this correspondence is being deposited with the  
United States Postal Service "Express Mail Post Office to Addressee"  
service under 37 C.F.R. 1.10 on the date indicated above and is addressed  
to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Christi A. Butner

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Günzberg et al.

Group Art Unit: 1632

**Serial No.: 08/999,690**

Examiner: Li, Qian Janice

Filed: September 8, 1997

Docket No.: 1406/205

Confirmation No.: 4218

For: **VECTORS CARRYING THERAPEUTIC GENES ENCODING ANTIMICROBIAL  
PEPTIDES FOR GENE THERAPY**

\*\*\*\*\*

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.


Appln. Serial No.: 08/999,690

Applicants submitted a Request for Continued Examination on May 9, 2005 and in accordance with 37 C.F.R. § 1.97 (b)(4) it is believed that no fee is due. However, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 05/23/2005

By:   
Arles A. Taylor, Jr.  
Registration No. 39,395


1406/205                      AAT/JD/cab

Enclosures

Customer No: 25297

**FORM PTO-1449 U.S. Department of Commerce**  
**Patent and Trademark Office**

List of Documents Cited by Applicant



Application No.:	08/999,690
Filing Date:	September 8, 1997
First Named Inventor:	Günzburg et al.
Group:	1632
Examiner:	Li, Qian Janice
Attorney Docket No.:	1406/205

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
	1.	5,863,904	01/26/1999	Nabel et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	2.	WO 95/00178	01/05/1995			
	3.	WO 94/29437	12/22/1994			
	4.	WO 95/13375	05/18/1995			
	5.	WO 95/06415	03/09/1995			
	6.	WO 93/12251	06/24/1993			
	7.	WO 89/11539	11/30/1989			
	8.	WO 96/37623	11/28/1996			
	9.	EP 0415731 A2	03/06/1991			

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	10.	ACHA-ORBEA et al., "Subversion of Host Immune Responses by Viral Superantigens", <u>Trends In Microbiology</u> , Vol. 1 (No. 1); 32-34, April 1993.	
	11.	KNIGHT et al., "Biochemical Analysis of the Mouse Mammary Tumor Virus Long Terminal Repeat Product. Evidence for the Molecular Structure of an Endogenous Superantigen", <u>European Journal of Immunology</u> , Vol. 22; 879-882, 1992.	

	12.	SALMONS et al., "Production of Mouse Mammary Tumor Virus upon Transfection of a Recombinant Proviral DNA into Cultured Cells", <u>Virology</u> , <b>Vol. 144</b> ; 101-114, 1985.	
	13.	KORMAN et al., "The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes a Type II Transmembrane Glycoprotein", <u>The EMBO Journal</u> , <b>Vol. 11 (No. 5)</b> ; 1901-1905, 1992.	
	14.	HORNSBY et al., "A Modified Procedure for Replica Plating of Mammalian Cells Allowing Selection of Clones Based on Gene Expression", <u>BioTechniques</u> , <b>Vol. 12 (No. 2)</b> ; 244-251, 1992.	
	15.	GÜNZBURG et al., "Factors Controlling the Expression of Mouse Mammary Tumour Virus", <u>Biochemical Journal</u> , <b>Vol. 283</b> ; 625-632, 1992.	
	16.	HUBER, Brigitte T., "Mls Genes and Self-Superantigens", <u>TIG</u> , <b>Vol. 8 (No. 11)</b> ; 399-402, November 1992.	
	17.	SALMONS et al., "Current Perspectives in the Biology of Mouse Mammary Tumour Virus", <u>Virus Research</u> , <b>Vol. 8</b> ; 81-102, 1987.	
	18.	WINTERSPERGER, et al., "Negative-acting Factor and Superantigen Are Separable Activities of the Mouse Mammary Tumor Virus Long Terminal Repeat", <u>Proceedings of the National Academy of Sciences</u> , <b>Vol. 92</b> ; 2745-2749, March 1995.	
	19.	DONEHOWER et al., "Regulatory and Coding Potential of the Mouse Mammary Tumor Virus Long Terminal Redundancy", <u>Journal of Virology</u> , <b>Vol. 37 (No. 1)</b> ; 226-238, January 1981.	
	20.	VILE et al., "In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells", <u>Cancer Research</u> , <b>Vol. 53 (No. 5)</b> ; 962-967 (abstract only), 1993.	
	21.	CHOI et al., "A Superantigen Encoded in the Open Reading Frame of the 3' Long Terminal Repeat of Mouse Mammary Tumour Virus", <u>Nature</u> , <b>Vol. 350</b> ; 203-207, March 1991.	
	22.	BRANDT-CARLSON et al., "Detection and Characterization of a Glycoprotein Encoded by the Mouse Mammary Tumor Virus Long Terminal Repeat Gene", <u>Journal of Virology</u> , <b>Vol. 65 (No. 11)</b> ; 6051-6060, November 1991.	
	23.	ACHA-ORBEA et al., "Clonal Deletion of V $\beta$ 14-bearing T Cells In Mice Transgenic for Mammary Tumour Virus", <u>Nature</u> , <b>Vol. 350</b> ; 207-211, March 1991.	
	24.	BRANDT-CARLSON et al., "Phylogenetic and Structural Analyses of MMTV LTR ORF Sequences of Exogenous and Endogenous Origins", <u>Virology</u> , <b>Vol. 193</b> ; 171-185, 1993.	

25.	KRUMMENACHER et al., "The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes A 47 kDa Glycoprotein With A Short Half-life In Mammalian Cells", <u>Molecular Immunology</u> , Vol. 30 (No. 13); 1151-1157, 1993.
26.	WINSLOW et al., "Detection and Biochemical Characterization of the Mouse Mammary Tumor Virus 7 Superantigen (Mls-1 <sup>a</sup> )", <u>Cell</u> , Vol. 71; 719-730, November 1992.
27.	WINSLOW et al., "Processing and Major Histocompatibility Complex Binding of the MTV7 Superantigen", <u>Immunity</u> , Vol. 1; 23-33, April 1994.
28.	KAY et al., "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-deficient Dogs", <u>Science</u> , Vol. 262 (No. 5130); 117-119, October 1993.
29.	PULLEN et al., "The Open Reading Frames in the 3' Long Terminal Repeats of Several Mouse Mammary Tumor Virus Integrants Encode Vβ3-specific Superantigens", <u>Journal of Experimental Medicine</u> , Vol. 175; 41-17, January 1992.
30.	MOHAN et al., "Production and Characterization of an Mls-1-specific Monoclonal Antibody", <u>Journal of Experimental Medicine</u> , Vol. 177; 351-358, February 1993.
31.	Genbank® Accession No. J02255
32.	Genbank® Accession No. M28246
33.	Genbank® Accession No. M28247
34.	Genbank® Accession No. M28248
35.	Definition of antisense DNA from <u>Stedman's Medical Dictionary</u>
36.	SCOTT et al., "Promoter-Proximal Poly (A) Sites Are Processed Efficiently, but the RNA Products Are Unstable in the Nucleus", <u>Molecular and Cellular Biology</u> , Vol. 17 (No. 4); 2127-2135, April 1997.
37.	FAUSTINELLA et al., "A New Family of Murine Retroviral Vectors with Extended Multiple Cloning Sites for Gene Insertion", <u>Human Gene Therapy</u> , Vol. 5; 307-312, 1994.
38.	MEHIGH et al., "Development of a Recombinant Bovine Leukemia Virus Vector for Delivery of a Synthetic Bovine Growth Hormone-Releasing Factor Gene into Bovine Cells", <u>Journal of Animal Science</u> , Vol. 71; 687-693, 1993.
39.	MEE et al., "Construction and Hormone Regulation of A Novel Retroviral Vector", <u>Gene</u> , Vol. 88; 289-292, 1990.
40.	PANGANIBAN et al., "The Retrovirus <i>pol</i> Gene Encodes A Product Required for DNA Integration: Identification of A Retrovirus <i>int</i> locus", <u>Proceedings from the National Academy of Sciences</u> , Vol. 81; 7885-7889, December 1984.

41.	LONGMORE et al., "Both Megakaryocytopoiesis and Erythropoiesis Are Induced in Mice Infected With a Retrovirus Expressing an Oncogenic Erythropoietin Receptor", <u>Blood</u> , <b>Vol. 82 (No. 8)</b> ; 2386-2395, October 1993.
42.	PANGANIBAN et al., "The Terminal Nucleotides of Retrovirus DNA Are Required for Integration But Not Virus Production", <u>Nature</u> , <b>Vol. 306</b> ; 155-160, November 1983.
43.	SCARPA et al., "Characterization of Recombinant Helper Retroviruses from Moloney-Based Vectors in Ecotropic and Amphotropic Packaging Cell Lines", <u>Virology</u> , <b>Vol. 180</b> ; 849-852, 1991.
44.	FELDER et al., "Functional and Biological Properties of an Avian Variant Long Terminal Repeat Containing Multiple A to G Conversions in the U3 Sequence", <u>Journal of Virology</u> , <b>Vol. 68 (No. 8)</b> ; 4759-4767, August 1994.
45.	HARPER et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases", <u>Cell</u> , <b>Vol. 75</b> ; 805-816, November 1993.
46.	MILLER et al., "Improved Retroviral Vectors for Gene Transfer and Expression", <u>BioTechniques</u> , <b>Vol. 7 (No. 9)</b> ; 980-990, 1989.
47.	PRICE et al., "Lineage Analysis in The Vertebrate Nervous System by Retrovirus-mediated Gene Transfer", <u>Proceedings from the National Academy of Sciences</u> , <b>Vol. 84</b> ; 156-160, January 1987.
48.	FELDMAN et al., "Prevention of Restenosis After Coronary Angioplasty: Towards a Molecular Approach", <u>Fundamental &amp; Clinical Pharmacology</u> , <b>Vol. 9</b> ; 8-16, 1995.
49.	CRYSTAL, Ronald F., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", <u>Science</u> , <b>Vol. 270</b> ; 404-410, 1995.
50.	TSANG et al., "Induction of Human Cytotoxic T Cell Lines Directed Against Point-Mutated p21 Ras-Derived Synthetic Peptides", <u>Vaccine Research</u> , <b>Vol. 3 (No. 4)</b> ; 183-193, 1994.
51.	HÄRTIG et al., "Regulation of Expression of Mouse Mammary Tumor Virus Through Sequences Located in the Hormone Response Element: Involvement of Cell-Cell Contact and a Negative Regulatory Factor", <u>Journal of Virology</u> , <b>Vol. 67 (No. 2)</b> ; 813-821, February 1993.
52.	NAKANISHI et al., "Identification of the Active Region of the DNA Synthesis Inhibitory Gene p21 <sup>Sdi1,CIP1/WAF1</sup> ", <u>The EMBO Journal</u> , <b>Vol. 14 (No. 3)</b> ; 555-563, 1995.
53.	NODA et al., "Cloning of Senescent Cell-Derived Inhibitors of DNA Synthesis Using an Expression Screen", <u>Experimental Cell Research</u> , <b>Vol. 211</b> ; 90-98, 1994.
54.	STANGE et al., "Prolonged Biochemical and Morphological Stability of Encapsulated Liver Cells - A New Method", <u>Biomaterials, Artificial Cells and Immobilization Biotechnology</u> , <b>Vol. 21 (No. 3)</b> ; 343-352, 1993.

55.	KATAYOSE et al., "Consequences of p53 Gene Expression By Adenovirus Vector On Cell Cycle Arrest and Apoptosis In Human Aortic Vascular Smooth Muscle Cells", <u>Biochemical And Biophysical Research Communications</u> , <b>Vol. 215 (No. 2)</b> ; 446-451, October 1995.
56.	BOND et al., "Mutant p53 Rescues Human Diploid Cells from Senescence Without Inhibiting the Induction of SD11/WAF1", <u>Cancer Research</u> , <b>Vol. 55</b> ; 2404-2409, June 1995.
57.	SKOTZKO et al., "Retroviral Vector-mediated Gene Transfer of Antisense Cyclin G1 (CYCG1) Inhibits Proliferation of Human Osteogenic Sarcoma Cells", <u>Cancer Research</u> , <b>Vol. 55</b> ; 5493-5498, December 1995.
58.	NAKANISHI et al., "Exit From G <sub>0</sub> and Entry Into the Cell Cycle of Cells Expressing p21 <sup>Sdi1</sup> Antisense RNA", <u>Proceedings from the National Academy of Sciences</u> , <b>Vol. 92</b> ; 4352-4356, May 1995.
59.	ZAKUT et al., "The Tumor Suppression Function of p21 <sup>Waf</sup> ('half-WAF')", <u>Oncogene</u> , <b>Vol. 11</b> ; 393-395, 1995.
60.	JOHNSON et al., "Evidence for a p53-Independent Pathway for Upregulation of SD11/CIP1/WAF1/p21 RNA in Human Cells", <u>Molecular Carcinogenesis</u> , <b>Vol. 11</b> ; 59-64, 1994.
61.	RUBELJ et al., "SV40-Transformed Human Cells in Crisis Exhibit Changes That Occur in Normal Cellular Senescence", <u>Experimental Cell Research</u> , <b>Vol. 211</b> ; 82-89, 1994.
62.	XIONG et al., "p21 Is a Universal Inhibitor of Cyclin Kinases", <u>Nature</u> , <b>Vol. 366</b> ; 701-704, December 1993.
63.	GÜNZBURG et al., "A Mammary-Specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia Cells in Transgenic Mice", <u>Molecular Endocrinology</u> , <b>Vol. 5 (No. 1)</b> ; 123-133, 1991.
64.	HUNTER, Tony, "Braking the Cycle", <u>Cell</u> , <b>Vol. 75</b> , 839-841, December 1993.
65.	EL-DEIRY et al., "WAF1, a Potential Mediator of p53 Tumor Suppression", <u>Cell</u> , <b>Vol. 75</b> ; 817-825, November 1993.
66.	JUNKER et al., "Genetic Instability of a MoMLV-based Antisense Double-copy Retroviral Vector Designed for HIV-1 Gene Therapy", <u>Gene Therapy</u> , <b>Vol. 2</b> ; 639-646, 1995.
67.	GÜNZBURG et al., "Retroviral Vectors Directed to Predefined Cell Types for Gene Therapy", <u>Biologicals</u> , <b>Vol. 23</b> ; 5-12, 1995.
68.	COUTURE et al., "Retroviral Vectors Containing Chimeric Promoter/Enhancer Elements Exhibit Cell-Type-Specific Gene Expression", <u>Human Gene Therapy</u> , <b>Vol 5</b> ; 667-677, 1994.



69.	SALMONS et al., "Targeting of Retroviral Vectors for Gene Therapy", <u>Human Gene Therapy</u> , Vol. 4; 129-141, 1993.
70.	CANNON et al., "Murine Leukemia Virus-Based Tat-Inducible Long Terminal Repeat Replacement Vectors: a New System for Anti-Human Immunodeficiency Virus Gene Therapy", <u>Journal of Virology</u> , Vol. 70 (No. 11); 8234-8240, November 1996.
71.	ROBINSON et al., "Retroviral Vector With a CMV-IE/HIV-TAR Hybrid LTR Gives High Basal Expression Levels and Is UP-Regulated by HIV-1 Tat", <u>Gene Therapy</u> , Vol. 2; 269-278, 1995.
72.	FERRARI et al., "A Retroviral Vector Containing a Muscle-Specific Enhancer Drives Gene Expression Only in Differentiated Muscle Fibers", <u>Human Gene Therapy</u> , Vol. 6; 733-742, June 1995.
73.	VILE et al., "Tissue-Specific Gene Expression from Mo-MLV Retroviral Vectors with Hybrid LTRs Containing the Murine Tyrosinase Enhancer/Promoter", <u>Virology</u> , Vol. 214; 307-313, 1995.
74.	GÜNZBURG et al., "Endogenous Superantigen Expression Controlled by a Novel Promoter in the MMTV Long Terminal Repeat", <u>Nature</u> , Vol. 364; 154-158, July 1993.
75.	SALMONS et al., "naf, a trans-Regulating Negative-Acting Factor Encoded Within the Mouse Mammary Tumor Virus Open Reading Frame Region", <u>Journal of Virology</u> , Vol. 64 (No. 12); 6355-6359, December 1990.
76.	Definition of "Provirus" from <u>Dorland's Illustrated Medical Dictionary</u> , 28 <sup>th</sup> Edition, W.B. Saunders Co., 1373, 1994.
77.	FASEL et al., "The Region of Mouse Mammary Tumor Virus DNA Containing the Long Terminal Repeat Includes a Long Coding Sequence and Signals for Hormonally Regulated Transcription", <u>The EMBO Journal</u> , Vol. 1 (No. 1); 3-7, 1982.
78.	WINTERSPERGER et al., "A Transient Assay for Gene Expression Studies in B Lymphocytes and It's use for Superantigen Assays", <u>BioTechniques</u> , Vol. 16 (No. 5), 882-886, 1994.
79.	Genbank® Accession No. V01175
80.	WINTERSPERGER et al., "Superantigen and NAF Activities of Mouse Mammary Tumour Virus Can Be Separated", <u>Journal of Cellular Biochemistry</u> , Supplemental 17D:54, March 1993.
81.	JANE et al., "Vector Development: A Major Obstacle in Human Gene Therapy", <u>Annals of Medicine</u> , Vol. 30 (No. 5); 413-415, October 1998.
82.	KAPLITT et al., "Genetic Modification of Cells with Retrovirus Vectors", <u>Viral Vectors</u> , M.G. Kaplitt et al., eds. (San Diego, CA: Academic Press, Inc.); 215-216 and 299, 1995.

	83.	GUNTAKA, Ramareddy V., "Transcription Termination and Polyadenylation in Retroviruses", <u>Microbiological Reviews</u> , Vol. 57 (No. 3); 511-521, September 1993.	
--	-----	--	--

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.